Positions

Overview

  • Dr. Craig Wilson joined UAB in 1991 after completing trainings in Pediatrics (Stanford University 1982-1986), Pediatric Infectious Diseases (Harvard University Boston Children’s Hospital 1986-1989) and post-doctoral training in molecular parasitology (Harvard School of Public Health 1987-1991). He had a primary appointment in Pediatrics (Infectious Diseases) and secondary appointments in Medicine (Geographic Medicine), Microbiology and Epidemiology and International Health.

    Dr. Craig Wilson joined the School of Public Health in 2007 and served as the Director of the Sparkman Center for Global Health (http://www.sparkmancenter.org) until retiring in 2018. Dr. Wilson had nearly 30 years of experience and expertise in international programs including molecular epidemiology of drug resistance in malaria and HIV prevention and management programs. He had secondary appointments in Pediatrics and Microbiology.

    Dr. Wilson had over 20 years of experience in a leadership role in HIV management and prevention in HIV infected and at-risk youth in the US. He was the innaugural Chair and PI of the Adolescent Medicine Trial Network for HIV/AIDS Interventions (ATN) from 2001-2018 and served on the NIH Division of AIDS Strategic Working Group (2006-2016), was appointed to the Office of AIDS Research Advisory Council (2011-2016) and served on the NIH Division of AIDS Youth Prevention Research Working Group 2012-2018 and was the innaugural co-chair. He was on multiple protocol teams testing HIV prevention methods and management strategies in youth and was co-chair for the FDA licensing trials of PrEP in adolescents.

    Dr. Wilson has an extensive background in HIV programs in sub-Saharan Africa and provided clinical and laboratory technical assistance to the UAB PEPFAR initiative in Zambia starting in 2004 through the Centre for Infectious Diseases Research in Zambia. He was the UAB PI of the NIH Fogarty International Center funded Medical Education Partnership Initiatives (MEPI) at the University of Zambia and Addis Ababa University from 2011-2016. He is presently working the same two African universities on the continuing Health Professional Education Partnership Initiatives (HEPI) funded from 2018-2023. He has served on many national and international advisory and planning panels for HIV prevention strategies and inclusion of youth in this planning.

    Dr Wilson worked on the challenges of lack of textbooks and poor or expensive internet access while working on education programs in Africa for over 10 years. Ultimately working with programmers in Zambia and Ethiopia they developed an open-source software to organize and disseminate educational resources in off-line formats called SparkEd . He is now working closely with collaborators in Ethiopia and the Ministry of Education to disseminate resources developed for Secondary Schools in Ethiopia (http://www.sparkmancenter.org) .
  • Selected Publications

    Academic Article

    Year Title Altmetric
    2021 High Prevalence of Anal High-Grade Squamous Intraepithelial Lesions, and Prevention Through Human Papillomavirus Vaccination, in Young Men Who Have Sex with Men Living with Human Immunodeficiency VirusClinical Infectious Diseases.  73:1388-1396. 2021
    2021 Cost-effectiveness of Frequent HIV Screening Among High-risk Young Men Who Have Sex With Men in the United StatesClinical Infectious Diseases.  73:E1927-E1935. 2021
    2020 Racial disparities and factors associated with prescription for smoking cessation medications among smokers receiving routine clinical care for HIV 2020
    2020 Prior incarceration associated with missed HIV care visits among young people living with HIV in the US 2020
    2020 Transmission Risk Among Youth Living With HIV in the U.S.Journal of Adolescent Health.  67:61-68. 2020
    2020 Changes in Bone Mass after Discontinuation of Preexposure Prophylaxis with Tenofovir Disoproxil Fumarate/Emtricitabine in Young Men Who Have Sex with Men: Extension Phase Results of Adolescent Trials Network Protocols 110 and 113Clinical Infectious Diseases.  70:687-691. 2020
    2020 Brief Report: Phase IIa Safety Study of a Vaginal Ring Containing Dapivirine in Adolescent Young Women 2020
    2019 Predictors of smoking cessation among people living with HIV receiving routine clinical care 2019
    2019 Mental health disorders and alcohol use are associated with increased likelihood of smoking relapse among people living with HIV attending routine clinical careBMC Public Health.  19. 2019
    2019 Pre-vaccination prevalence of anogenital and oral human papillomavirus in young HIV-infected men who have sex with menTumour Virus Research.  7:52-61. 2019
    2019 A measure to assess HIV treatment readiness among adolescents and young adultsVulnerable Children and Youth Studies.  14:142-150. 2019
    2019 Brief Report: Role of Sociobehavioral Factors in Subprotective TFV-DP Levels Among YMSM Enrolled in 2 PrEP Trials. 2019
    2019 Role of sociobehavioral factors in subprotective TFV-DP Levels among YMSM Enrolled in 2 PrEP Trials 2019
    2019 Short Communication: Association of Vitamin D Insufficiency and Protective Tenofovir Diphosphate Concentrations with Bone Toxicity in Adolescent Boys and Young Men Using Tenofovir Disoproxil Fumarate/Emtricitabine for HIV Pre-Exposure ProphylaxisAIDS Research and Human Retroviruses.  35:123-128. 2019
    2018 Enzymes of pyrimidine salvage pathways in intraerythrocytic Plasmodium falciparum 2018
    2018 Correlates of Serodiscordant Condomless Anal Intercourse Among Virologically Detectable HIV-Positive Young Men Who Have Sex with MenAIDS and Behavior.  22:3535-3539. 2018
    2018 A cross-sectional study examining associations between substance use frequency, problematic use and STIs among youth living with HIVSexually Transmitted Infections.  94:304-308. 2018
    2018 HIV-Infected Young Men Demonstrate Appropriate Risk Perceptions and Beliefs about Safer Sexual Behaviors after Human Papillomavirus VaccinationAIDS and Behavior.  22:1826-1834. 2018
    2018 Tobacco Use and Sustained Viral Suppression in Youth Living with HIVAIDS and Behavior.  22:2018-2025. 2018
    2018 In replyJAMA Pediatrics.  172:391-392. 2018
    2018 Linking HIV-Negative Youth to Prevention Services in 12 U.S. Cities: Barriers and Facilitators to Implementing the HIV Prevention ContinuumJournal of Adolescent Health.  62:424-433. 2018
    2018 Comparison of Measures of Adherence to Human Immunodeficiency Virus Preexposure Prophylaxis among Adolescent and Young Men Who Have Sex with Men in the United StatesClinical Infectious Diseases.  66:213-219. 2018
    2018 Vitamin D3 Supplementation Increases Spine Bone Mineral Density in Adolescents and Young Adults with Human Immunodeficiency Virus Infection Being Treated with Tenofovir Disoproxil Fumarate: A Randomized, Placebo-Controlled TrialClinical Infectious Diseases.  66:220-228. 2018
    2018 HIV Continuum of Care for Youth in the United States 2018
    2018 Partner Notification for Youth Living With HIV in 14 Cities in the United States 2018
    2018 Tenofovir disoproxil fumarate appears to disrupt the relationship of Vitamin D and parathyroid hormoneAntiviral Therapy.  23:623-6928. 2018
    2017 Safety and feasibility of antiretroviral preexposure prophylaxis for adolescent men who have sex with men aged 15 to 17 years in the United StatesJAMA Pediatrics.  171:1063-1071. 2017
    2017 Implementation of an integrated approach to the national HIV/AIDS strategy for improving human immunodeficiency virus care for youthsJAMA Pediatrics.  171:687-693. 2017
    2017 Strengthening and expanding the capacity of health worker education in ZambiaThe Pan African Medical Journal.  27. 2017
    2017 Evaluating testing strategies for identifying youths with HIV infection and linking youths to biomedical and other prevention servicesJAMA Pediatrics.  171:532-537. 2017
    2017 Decline in bone mass with tenofovir disoproxil fumarate/emtricitabine is associated with hormonal changes in the absence of renal impairment when used by HIV-uninfected adolescent boys and young men for HIV preexposure prophylaxisClinical Infectious Diseases.  64:317-325. 2017
    2017 An HIV Preexposure Prophylaxis Demonstration Project and Safety Study for Young MSM 2017
    2016 Emtricitabine-Triphosphate in dried blood spots as a marker of recent dosingAntimicrobial Agents and Chemotherapy.  60:6692-6697. 2016
    2016 Preventing HIV among adolescents with oral PrEP: Observations and challenges in the United States and South AfricaJournal of the International AIDS Society.  19. 2016
    2016 Antiretroviral treatment initiation does not differentially alter neurocognitive functioning over time in youth with behaviorally acquired HIVJournal of NeuroVirology.  22:218-230. 2016
    2016 Sexual risk behavior among virologically detectable human immunodeficiency virus-infected young men who have sex with menJAMA Pediatrics.  170:125-131. 2016
    2015 Factors Associated With Smoking Status among HIV-Positive Patients in Routine Clinical Care.Journal of AIDS and Clinical Research.  6. 2015
    2015 Mitochondrial DNA diversity in the African American populationMitochondrial DNA Part A.  26:445-451. 2015
    2015 Immune reconstitution but persistent activation after 48 weeks of antiretroviral therapy in youth with pre-therapy CD4 >350 in ATN 061 2015
    2015 Rates and correlates of antiretroviral therapy use and virologic suppression among perinatally and behaviorally HIV-infected youth linked to care in the United States 2015
    2015 How we implemented an analytical support clinic to strengthen student research capacity in ZambiaMedical Teacher.  37:635-640. 2015
    2014 Mitochondrial DNA variation and virologic and immunological HIV outcomes in African AmericansAIDS.  28:1871-1878. 2014
    2014 KIR2DS4 promotes HIV-1 pathogenesis: New evidence from analyses of immunogenetic data and natural killer cell functionPLoS One.  9. 2014
    2014 Vitamin D3 supplementation increases fibroblast growth factor-23 in HIV-infected youths treated with tenofovir disoproxil fumarateAntiviral Therapy.  19:613-618. 2014
    2013 Genetic associations with 25-hydroxyvitamin D deficiency in HIV-1-infected youth: Fine-mapping for the GC/DBP gene that encodes the vitamin D-binding proteinFrontiers in Genetics.  4. 2013
    2013 Oral Lesions: Poor Markers of Virologic Failure in HIV-Infected Patients on Antiretroviral TherapyISRN Infectious Diseases.  2013:1-7. 2013
    2013 Association of higher plasma vitamin d binding protein and lower free calcitriol levels with tenofovir disoproxil fumarate use and plasma and intracellular tenofovir pharmacokinetics: Cause of a functional Vitamin D deficiency?Antimicrobial Agents and Chemotherapy.  57:5619-5628. 2013
    2013 Variants in interleukin family of cytokines genes influence clearance of high risk HPV in HIV-1 coinfected African-American adolescentsHuman Immunology.  74:1696-1700. 2013
    2013 Immunogenicity and safety of the human papillomavirus 6, 11, 16, 18 vaccine in HIV-infected young womenClinical Infectious Diseases.  57:735-744. 2013
    2013 Incident anal human papillomavirus and human papillomavirus-related sequelae in HIV-infected versus HIV-uninfected adolescents in the United StatesSexually Transmitted Diseases.  40:715-720. 2013
    2013 The acceptability and feasibility of an HIV preexposure prophylaxis (PrEP) trial with young men who have sex with men 2013
    2013 Assessment of biomarkers of cardiovascular risk among HIV type 1-infected adolescents: Role of soluble vascular cell adhesion molecule as an early indicator of endothelial inflammationAIDS Research and Human Retroviruses.  29:493-500. 2013
    2013 Incidence of sexually transmitted infections in HIV-infected and HIV-uninfected adolescents in the USAInternational Journal of STD and AIDS.  24:123-127. 2013
    2013 Comprehension of a simplified assent form in a vaccine trial for adolescentsJournal of Medical Ethics.  39:410-412. 2013
    2012 Prevalence of proteinuria and elevated serum cystatin c among hiv-infected adolescents in the reaching for Excellence in Adolescent Care and Health (REACH) study 2012
    2012 Toll-like receptor gene variants associated with bacterial vaginosis among HIV-1 infected adolescentsJournal of Reproductive Immunology.  96:84-89. 2012
    2012 Serum 25-hydroxyvitamin D response to vitamin D3 supplementation 50,000 IU monthly in youth with HIV-1 infectionJournal of Clinical Endocrinology and Metabolism.  97:4004-4013. 2012
    2012 Low bone mass in behaviorally HIV-infected young men on antiretroviral therapy: Adolescent trials network study 021BClinical Infectious Diseases.  55:461-468. 2012
    2012 Incidence, prevalence, and epidemiology of herpes simplex virus-2 in HIV-1-positive and HIV-1-negative adolescentsSexually Transmitted Diseases.  39:300-305. 2012
    2012 Substantial multiclass transmitted drug resistance and drug-relevant polymorphisms among treatment-naïve behaviorally HIV-infected youth 2012
    2012 Vitamin D3 decreases parathyroid hormone in HIV-infected youth being treated with tenofovir: A randomized, placebo-controlled trialClinical Infectious Diseases.  54:1013-1025. 2012
    2012 Transitional probability-based model for HPV clearance in HIV-1-positive adolescent femalesPLoS One.  7. 2012
    2012 Prevalence and risk factors for HPV in HIV-positive young women receiving their first HPV vaccination. 2012
    2011 Contemporary profile of oral manifestations of HIV/AIDS and associated risk factors in a southeastern US clinicJournal of Public Health Dentistry.  71:257-264. 2011
    2011 Prevalence, incidence, and recurrence of oral lesions among HIV-infected patients on HAART in Alabama: A two-year longitudinal studySouthern Medical Journal.  104:561-566. 2011
    2011 Identification of three immunologic correlates for HIV type 1 pathogenesis in YouthAIDS Research and Human Retroviruses.  27:639-646. 2011
    2011 Hepatitis B vaccination in HIV-infected youth: A randomized trial of three regimens 2011
    2011 The influence of human leukocyte antigen class I alleles and their population frequencies on human immunodeficiency virus type 1 control among African AmericansHuman Immunology.  72:312-318. 2011
    2011 Hormonal contraceptive use and response to antiretroviral therapy among adolescent females 2011
    2011 The Zambian HIV Nurse practitioner diploma program: Preliminary outcomes from first cohort of Zambian NursesInternational Journal of Nursing Education Scholarship.  8. 2011
    2010 Interleukin-10 (IL-10) pathway: Genetic variants and outcomes of HIV-1 infection in African American adolescentsPLoS One.  5. 2010
    2010 Association between Anemia and Aflatoxin B-1 Biomarker Levels among Pregnant Women in Kumasi, GhanaAmerican Journal of Tropical Medicine and Hygiene.  83:1077-1083. 2010
    2010 The impact of highly active antiretroviral therapy on prevalence and incidence of cervical human papillomavirus infections in HIV-positive adolescentsBMC Infectious Diseases.  10. 2010
    2010 Epidemiology of HIV infection and risk in adolescents and youth 2010
    2010 Human leukocyte antigen class I supertypes and HIV-1 control in African AmericansJournal of Virology.  84:2610-2617. 2010
    2010 Association between birth outcomes and aflatoxin B1 biomarker blood levels in pregnant women in Kumasi, GhanaTropical Medicine and International Health.  15:160-167. 2010
    2010 Demographic Profiles of Newly Acquired HIV Infections Among Adolescents and Young Adults in the U.S.Journal of Adolescent Health.  46:93-96. 2010
    2010 Obesity and dyslipidemia in behaviorally HIV-infected young women: Adolescent trials network study 021Clinical Infectious Diseases.  50:106-114. 2010
    2010 Randomized trial to determine safety and immunogenicity of two strategies for hepatitis B vaccination in healthy Urban adolescents in the United States 2010
    2009 Predictors of suboptimal virologic response to highly active antiretroviral therapy among human immunodeficiency virus-infected adolescents: Analyses of the Reaching for Excellence in Adolescent Care and Health (REACH) ProjectJAMA Pediatrics.  163:1100-1105. 2009
    2009 Clear and independent associations of several HLA-DRB1 alleles with diVerential antibody responses to hepatitis B vaccination in youthHuman Genetics.  126:685-696. 2009
    2009 Short-cycle therapy in adolescents after continuous therapy with established viral suppression: The impact on viral load suppressionAIDS Research and Human Retroviruses.  25:555-561. 2009
    2009 Host genetics and HIV-1 viral load set-point in African-AmericansAIDS.  23:673-677. 2009
    2008 Immunogenetic correlates of neisseria gonorrhoeae infection in adolescentsSexually Transmitted Diseases.  35:656-661. 2008
    2008 Surgically induced necrotizing scleritis after pterygium surgery with conjunctival autograft.Cornea.  27:720-721. 2008
    2008 Pharmacokinetics of antiretroviral regimens containing tenofovir disoproxil fumarate and atazanavir-ritonavir in adolescents and young adults with human immunodeficiency virus infectionAntimicrobial Agents and Chemotherapy.  52:631-637. 2008
    2008 Inclusion of adolescents in preventive HIV vaccine trials: Public health policy and research design at a crossroadsCornea.  47:86-92. 2008
    2007 Immunological control of chronic HIV-1 infection: HLA-mediated immune function and viral evolution in adolescentsAIDS.  21:2387-2397. 2007
    2007 Clinical outcomes and CD4 cell response in children receiving antiretroviral therapy at primary health care facilities in ZambiaJournal of the American Medical Association.  298:1888-1899. 2007
    2007 HIV voluntary counseling and testing among injection drug users in south China: A study of a non-government organization based programAIDS and Behavior.  11:778-788. 2007
    2007 Interleukin-10 gene (IL10) polymorphisms and human papillomavirus clearance among immunosuppressed adolescentsCancer Epidemiology, Biomarkers and Prevention.  16:1626-1632. 2007
    2007 Calibration and validation of an oral fluid-based sensitive/less-sensitive assay to distinguish recent from established HIV-1 infectionsJournal of Clinical Laboratory Analysis.  21:40-45. 2007
    2007 CCL3L1 and CCL4L1: Variable gene copy number in adolescents with and without human immunodeficiency virus type 1 (HIV-1) infectionGenes and Immunity.  8:224-231. 2007
    2007 Glutathione, glutathione peroxidase, and selenium status in HIV-positive and HIV-negative adolescents and young adultsAmerican Journal of Clinical Nutrition.  85:173-181. 2007
    2006 Prevalence of primary HIV-1 drug resistance among recently infected adolescents: A Multicenter Adolescent Medicine Trials Network for HIV/AIDS Interventions StudyJournal of Infectious Diseases.  194:1505-1509. 2006
    2006 Cohort- and time-specific associations of CTLA4 genotypes with HIV-1 disease progressionAIDS.  20:1583-1590. 2006
    2006 HIV-1 epitope-specific CD8+ T cell responses strongly associated with delayed disease progression cross-recognize epitope variants efficientlyJournal of Immunology.  176:6130-6146. 2006
    2006 Vitamin D status in adolescents and young adults with HIV infectionAmerican Journal of Clinical Nutrition.  83:1135-1141. 2006
    2006 Interleukin 18 and human immunodeficiency virus type I infection in adolescents and adultsClinical and Experimental Immunology.  144:117-124. 2006
    2006 Vitamins C and E in adolescents and young adults with HIV infectionAmerican Journal of Clinical Nutrition.  83:870-879. 2006
    2006 Immune reconstitution and predictors of virologic failure in adolescents infected through risk behaviors and initiating HAART: Week 60 results from the PACTG 381 cohortAIDS Research and Human Retroviruses.  22:213-221. 2006
    2006 Group M-based HIV-1 Gag peptides are frequently targeted by T cells in chronically infected US and Zambian patientsAIDS.  20:353-360. 2006
    2005 Interleukin (IL)-2 and IL-12 responses to Chlamydia trachomatis infection in adolescentsClinical and Experimental Immunology.  142:548-554. 2005
    2005 Longitudinal antiretroviral adherence among adolescents infected with human immunodeficiency virusJAMA Pediatrics.  159:764-770. 2005
    2005 Plasma cytokines and oxidative damage in HIV-positive and HIV-negative adolescents and young adults: A protective role for IL-10? 2005
    2005 Human leukocyte antigen and cytokine gene variants as predictors of recurrent Chlamydia trachomatis infection in high-risk adolescentsJournal of Infectious Diseases.  191:1084-1092. 2005
    2005 CD8 T-cell responses in early HIV-1 infection are skewed towards high entropy peptidesAIDS.  19:241-250. 2005
    2005 Immune activation and oxidative damage in HIV-positive and HIV-negative adolescents 2005
    2004 Epidemiological and genetic correlates of incident Chlamydia trachomatis infection in North American adolescentsJournal of Infectious Diseases.  190:1723-1729. 2004
    2004 HIV-infected US youth are at high risk of obesity and poor diet quality: A challenge for improving short- and long-term health outcomesJournal of the Academy of Nutrition and Dietetics.  104:1554-1560. 2004
    2004 US youths in the early stages of HIV disease have low intakes of some micronutrients important for optimal immune functionJournal of the Academy of Nutrition and Dietetics.  104:1095-1101. 2004
    2004 Cytokine and Chemokine Gene Polymorphisms among Ethnically Diverse North Americans with HIV-1 Infection 2004
    2004 HLA and Cytokine Gene Polymorphisms Are independently Associated with Responses to Hepatitis B VaccinationHepatology.  39:978-988. 2004
    2004 CD8+CD88+ T cells but not HIV type 1 RNA viral load predict CD4+ T cell loss in a predominantly minority female HIV + adolescent populationAIDS Research and Human Retroviruses.  20:263-269. 2004
    2004 Tolerance and Safety of Different Concentrations of Chlorhexidine for Peripartum Vaginal and Infant Washes: HIVNET 025 2004
    2003 T Cell Responses in HIV Type 1-Infected Adolescent Minorities Share Similar Epitope Specificities with Whites Despite Significant Differences in HLA Class I AllelesAIDS Research and Human Retroviruses.  19:1017-1026. 2003
    2003 Cross-reactive CD8+ T cell epitopes identified in US adolescent minorities 2003
    2003 CD4+ and CD8+ T cell receptor repertoire perturbations with normal levels of T cell receptor excision circles in HIV-infected, therapy-naive adolescentsAIDS Research and Human Retroviruses.  19:487-495. 2003
    2003 TH1 and TH2 cytokine mRNA and protein levels in human immunodeficiency virus (HIV)-seropositive and HIV-seronegative youthsClinical and Vaccine Immunology.  10:399-404. 2003
    2003 Delayed onset of pubertal development in children and adolescents with perinatally acquired HIV infection 2003
    2003 The relationships between substance abuse, psychosocial variables, and natural killer cell enumeration and function in HIV-infected and high-risk uninfected adolescentsAIDS Research and Human Retroviruses.  19:399-408. 2003
    2003 Assessment of thymic activity in human immunodeficiency virus-negative and -positive adolescents by real-time PCR quantitation of T-cell receptor rearrangement excision circlesClinical and Vaccine Immunology.  10:323-328. 2003
    2003 Barriers to HAART adherence among human immunodeficiency virus - Infected adolescentsJAMA Pediatrics.  157:249-255. 2003
    2003 Human papillomavirus infection and abnormal cytology of the anus in HIV-infected and uninfected adolescentsAIDS.  17:311-320. 2003
    2002 Increased proliferation within T lymphocyte subsets of HIV-infected adolescentsAIDS Research and Human Retroviruses.  18:1301-1310. 2002
    2002 Host genetic profiles predict virological and immunological control of HIV-1 infection in adolescentsAIDS.  16:2275-2284. 2002
    2002 Barriers to HIV testing - Where next? 2002
    2002 Peripheral blood lymphocyte subsets in adolescents: A longitudinal analysis from the REACH projectClinical and Vaccine Immunology.  9:959-965. 2002
    2002 CCR2 and CCR5 genotypes in HIV type 1-infected adolescents: Limited contributions to variability in plasma HIV type 1 RNA concentration in the absence of antiretroviral therapyAIDS Research and Human Retroviruses.  18:403-412. 2002
    2001 HIV-related oral manifestations among adolescents in a multicenter cohort studyJournal of Adolescent Health.  29:109-114. 2001
    2001 Douching practices among HIV infected and uninfected adolescents in the United StatesJournal of Adolescent Health.  29:80-86. 2001
    2001 Serologic response to hepatitis B vaccine in HIV infected and high-risk HIV uninfected adolescents in the REACH cohortJournal of Adolescent Health.  29:123-129. 2001
    2001 Sexually transmitted infections among HIV infected and HIV uninfected high-risk youth in the REACH studyJournal of Adolescent Health.  29:49-56. 2001
    2001 The REACH (Reaching for Excellence in Adolescent Care and Health) project: Study design, methods, and population profileJournal of Adolescent Health.  29:8-18. 2001
    2001 Performance of antigens used in detecting delayed-type hypersensitivity in adolescents infected with the human immunodeficiency virusClinical and Vaccine Immunology.  8:273-278. 2001
    2001 Antiretroviral medication adherence among the REACH HIV-infected adolescent cohort in the USA 2001
    2001 Natural killer cell enumeration and function in HIV-infected and high-risk uninfected adolescentsAIDS Research and Human Retroviruses.  17:543-552. 2001
    2000 Marijuana use among HIV-positive and high-risk adolescents: A comparison of self-report through audio computer-assisted self-administered interviewing and urinalysisAmerican Journal of Epidemiology.  152:805-813. 2000
    2000 Relationship of CD4+ T cell counts and HIV type 1 viral loads in untreated, infected adolescentsAIDS Research and Human Retroviruses.  16:959-963. 2000
    2000 Pinworm (Enterobius vermicularis)Seminars in pediatric infectious diseases.  11:252-256. 2000
    2000 Prevalence of and risks for cervical human papillomavirus infection and squamous intraepithelial lesions in adolescent girls: Impact of infection with human immunodeficiency virusJAMA Pediatrics.  154:127-134. 2000
    2000 Seroprevalence and risk factors of hepatitis B, hepatitis C, and human cytomegalovirus among HIV-infected and high-risk uninfected adolescents: Findings of the reach studySexually Transmitted Diseases.  27:296-303. 2000
    2000 T-lymphocyte subsets in HIV-infected and high-risk HIV-uninfected adolescents: Retention of naive T lymphocytes in HIV-infected adolescentsJAMA Pediatrics.  154:375-380. 2000
    2000 The prevalence of anergy in Human Immunodeficiency Virus-infected adolescents and the association of delayed-type hypersensitivity with subject characteristicsJournal of Adolescent Health.  27:384-390. 2000
    1999 The adenosine transporter of Toxoplasma gondii. Identification by insertional mutagenesis, cloning, and recombinant expressionJournal of Biological Chemistry.  274:35255-35261. 1999
    1999 Insertional tagging of at least two loci associated with resistance to adenine arabinoside in Toxoplasma gondii, and cloning of the adenosine kinase locusMolecular and Biochemical Parasitology.  103:1-14. 1999
    1999 Peripheral blood mononuclear cell markers in antiretroviral therapy-naive HIV-infected and high risk seronegative adolescentsAIDS.  13:1629-1635. 1999
    1998 The REACH Project of the Adolescent Medicine HIV/AIDS Research Network: Design, methods, and selected characteristics of participantsJournal of Adolescent Health.  22:300-311. 1998
    1997 Mutations in dihydropteroate synthase are responsible for sulfone and sulfonamide resistance in Plasmodium falciparum 1997
    1996 Characterization of the δ-aminolevulinate synthase gene homologue in P. falciparumMolecular and Biochemical Parasitology.  75:271-275. 1996
    1996 Molecular characterization of airport malariaJournal of Travel Medicine.  3:179-181. 1996
    1996 Plasmodium falciparum: Molecular characterization of multidrug-resistant Cambodian isolatesExperimental Parasitology.  82:97-103. 1996
    1995 Analysis of pfmdr1 and drug susceptibility in fresh isolates of Plasmodium falciparum from Subsaharan AfricaMolecular and Biochemical Parasitology.  74:157-166. 1995
    1995 Point mutations in the dihydrofolate reductase-thymidylate synthase gene and pyrimethamine and cycloguanil resistance in Plasmodium falciparumMolecular and Biochemical Parasitology.  69:135-138. 1995
    1994 Characterization of the pfmdr2 gene for Plasmodium falciparumMolecular and Biochemical Parasitology.  63:311. 1994
    1994 Respiratory distress caused by parasites. 1994
    1993 Cross-reactivity between Stomatococcus mucilaginosus and latex agglutination for cryptococcal antigen 1993
    1993 Amplification of pfmdr1 associated with mefloquine and halofantrine resistance in Plasmodium falciparum from ThailandMolecular and Biochemical Parasitology.  57:151-160. 1993
    1993 Characterization of the pfmdr 2 gene for Plasmodium falciparumMolecular and Biochemical Parasitology.  62:83-92. 1993
    1993 Stage-specific transcripts of the Plasmodium falciparum pfmdr1 geneMolecular and Biochemical Parasitology.  57:203-211. 1993
    1993 The dihydroorotate dehydrogenase gene homologue of Plasmodium falciparumMolecular and Biochemical Parasitology.  60:349-351. 1993
    1991 Successful treatment of disseminated Fusarium infection after autologous bone marrow transplantation for acute myeloid leukemiaBone Marrow Transplantation.  8:143-145. 1991
    1990 Scedosporium inflatum: Clinical spectrum of a newly recognized pathogenJournal of Infectious Diseases.  161:102-107. 1990
    1989 A concurrent epidemic of respiratory syncytial virus and echovirus 7 infections in an intensive care nursery 1989
    1989 Amplification of a gene related to mammalian mdr genes in drug-resistant Plasmodium falciparumScience.  244:1184-1186. 1989
    1987 A technique for the administration of ribavirin to mechanically ventilated infants with severe respiratory syncytial virus infectionCritical Care Medicine.  15:1051-1054. 1987

    Chapter

    Year Title Altmetric
    2015 Giardiasis 2015
    2015 Pinworm Infestations 2015
    2012 Antiparasitic Agents.  1518-1545.e3. 2012

    Research Overview

  • Dr. Wilson’s early research focused on the molecular epidemiology of drug resistance in malaria parasites including the first identification of mdr-like genes in malaria (1989). Dr. Wilson’s lab at UAB was involved in the molecular identification and characterization of the first nutrient transporter characterized in any protozoan parasite (1999). Dr Wilson also was the first to describe the clinical presentations of a newly identified fungal pathogen in humans (1990).
    Dr. Wilson began to work on the challenges of HIV prevention and management in youth in 1996 and continued this work through his retirement. He was PI of the Data and Operations Center for the REACH project (1996-2003) and Innaugural Chair of the Adolescent Medicine Trials Network for HIV/AIDS Interventions (ATN) from 2001-2018. His collaborative work within these networks resulted in over 120 personal peer reviewed manuscripts and over 300 total publications.

    Dr. Wilson has had a leadership and advisory role on issues related to HIV in adolescents, trials and approaches to studies in adolescents and vulnerable populations and biomedical trials in developing countries. In this regard, he served on the NIH Office of AIDS Research Advisory Council from 2011-2016, NIH Division of AIDS Strategic Working Group from 2006–2016, on World Health Organization (WHO) panel on the ethics of vaccine trials in developing countries in 2002 and other international panels on HIV prevention trials in developing countries, and on NIH advisory and review panels on the domestic adolescent HIV research agenda and its implementation
  • Teaching Overview

  • Dr. Wilson directed the establishment of the UAB School of Public Health Graduate Certificate in Global Health in 2009 and the establishment of the Global Health Concentration in the Public Health major in 2014. Dr. Wilson worked closely with the School of Public Health leadership to establish and develop the Public Health undergraduate major.
    Dr. Wilson taught graduate and undergraduate courses in Global Health and Global Infectious Diseases and lectured in many courses on infectious diseases related topics including HIV and HPV.
  • Teaching Activities

  • EPI604 - Infec. Dis:Fld Stdy in Dev Cty (Summer Term 2009)
  • EPI650 - GLB PERS DIS PRV/CON (Summer Term 2009)
  • EPI650 - GLB PERS DIS PRV/CON (Summer Term 2010)
  • EPI697 - Internship (Fall Term 2012)
  • EPI697 - Internship (Fall Term 2013)
  • EPI697 - Internship (Fall Term 2017)
  • EPI697 - Internship (Spring Term 2012)
  • EPI697 - Internship (Spring Term 2014)
  • EPI697 - Internship (Summer Term 2009)
  • EPI697 - Internship (Summer Term 2010)
  • EPI697 - Internship (Summer Term 2011)
  • EPI697 - Internship (Summer Term 2012)
  • EPI697 - Internship (Summer Term 2013)
  • EPI697 - Internship (Summer Term 2015)
  • EPI697 - Internship (Summer Term 2017)
  • EPI698 - Directed Research (Fall Term 2010)
  • EPI698 - Directed Research (Fall Term 2011)
  • EPI698 - Directed Research (Fall Term 2012)
  • EPI698 - Directed Research (Spring Term 2013)
  • EPI698 - Directed Research (Summer Term 2012)
  • EPI698 - Directed Research (Summer Term 2013)
  • EPI699 - Project Research (Fall Term 2016)
  • EPI699 - Project Research (Summer Term 2017)
  • EPI793 - DrPH Practicum (Fall Term 2012)
  • EPI793 - DrPH Practicum (Fall Term 2014)
  • EPI798 - Doctoral Directed Research (Fall Term 2010)
  • EPI798 - Doctoral Directed Research (Fall Term 2011)
  • EPI798 - Doctoral Directed Research (Fall Term 2012)
  • EPI798 - Doctoral Directed Research (Fall Term 2013)
  • EPI798 - Doctoral Directed Research (Spring Term 2010)
  • EPI798 - Doctoral Directed Research (Spring Term 2011)
  • EPI798 - Doctoral Directed Research (Spring Term 2012)
  • EPI798 - Doctoral Directed Research (Spring Term 2013)
  • EPI798 - Doctoral Directed Research (Spring Term 2014)
  • EPI798 - Doctoral Directed Research (Summer Term 2010)
  • EPI798 - Doctoral Directed Research (Summer Term 2011)
  • EPI798 - Doctoral Directed Research (Summer Term 2012)
  • EPI798 - Doctoral Directed Research (Summer Term 2013)
  • EPI798 - Doctoral Directed Research (Summer Term 2014)
  • EPI798 - Doctoral Directed Research (Summer Term 2014)
  • EPI798 - Doctoral Directed Research (Summer Term 2015)
  • EPI799 - Dissertation Research (Fall Term 2009)
  • EPI799 - Dissertation Research (Fall Term 2010)
  • EPI799 - Dissertation Research (Fall Term 2013)
  • EPI799 - Dissertation Research (Fall Term 2014)
  • EPI799 - Dissertation Research (Fall Term 2015)
  • EPI799 - Dissertation Research (Spring Term 2010)
  • EPI799 - Dissertation Research (Spring Term 2013)
  • EPI799 - Dissertation Research (Spring Term 2014)
  • EPI799 - Dissertation Research (Spring Term 2015)
  • EPI799 - Dissertation Research (Summer Term 2009)
  • EPI799 - Dissertation Research (Summer Term 2010)
  • EPI799 - Dissertation Research (Summer Term 2013)
  • EPI799 - Dissertation Research (Summer Term 2015)
  • GHS401 - Communicable Disease (Spring Term 2015)
  • GHS420 - Field Studies: Jamaica (Summer Term 2014)
  • GHS600 - Fund Glbl Hlth Prog/Pol/Practi (Summer Term 2011)
  • GHS600 - Fundamenatls of Glbl Hlth: (Summer Term 2010)
  • GHS600 - Fundamentals of Global Health (Spring Term 2014)
  • GHS600 - Fundamentals of Global Health (Spring Term 2015)
  • GHS600 - Fundamentals of Global Health (Summer Term 2012)
  • GHS600 - Fundamentals of Global Health (Summer Term 2013)
  • GHS600 - Fundamentals of Global Health (Summer Term 2014)
  • GHS600 - Fundamentals of Global Health (Summer Term 2015)
  • GHS600 - Fundamentals of Global Health (Summer Term 2016)
  • GHS602 - Intro Applied Res Glob Hlth (Summer Term 2010)
  • GHS604 - Infect Diseas of Glb Hlth Sign (Spring Term 2011)
  • GHS604 - Infect Diseas of Glb Hlth Sign (Spring Term 2012)
  • GHS604 - Infect Diseas of Glb Hlth Sign (Spring Term 2013)
  • GHS604 - Infect Diseas of Glb Hlth Sign (Spring Term 2014)
  • GHS604 - Infect Diseas of Glb Hlth Sign (Spring Term 2015)
  • GHS604 - Infect Diseas of Glb Hlth Sign (Spring Term 2016)
  • GHS604 - Infect Diseas of Glb Hlth Sign (Spring Term 2017)
  • GHS604 - Infect Diseas of Glb Hlth Sign (Spring Term 2018)
  • GHS605 - Disabilities and Global Health (Summer Term 2010)
  • GHS605 - Disabilities and Global Health (Summer Term 2011)
  • GHS605 - Disabilities and Global Health (Summer Term 2012)
  • GHS606 - Crit Issues Globl MCH (Fall Term 2010)
  • GHS606 - Crit Issues Globl MCH (Fall Term 2011)
  • GHS606 - Crit Issues Globl MCH (Fall Term 2012)
  • GHS609 - Environ Hlth Issue Res Lim Set (Fall Term 2010)
  • GHS609 - Environ Hlth Issue Res Lim Set (Fall Term 2011)
  • GHS609 - Environ Hlth Issue Res Lim Set (Fall Term 2012)
  • GHS610 - Refugee Health (Fall Term 2010)
  • GHS610 - Refugee Health (Fall Term 2011)
  • GHS610 - Refugee Health (Fall Term 2012)
  • GHS611 - International NGO Management (Spring Term 2013)
  • GHS617 - Global Health:Princ & Prac (Fall Term 2009)
  • GHS617 - Global Health:Princ & Prac (Fall Term 2010)
  • GHS617 - Global Health:Princ & Prac (Fall Term 2011)
  • GHS617 - Global Health:Princ & Prac (Fall Term 2012)
  • GHS618 - Glob Hlth: Prin & Prac II (Spring Term 2010)
  • GHS618 - Glob Hlth: Prin & Prac II (Spring Term 2011)
  • GHS618 - Glob Hlth: Prin & Prac II (Spring Term 2012)
  • GHS620 - Infect Dis Surveillane & Contr (Summer Term 2013)
  • GHS620 - Infect Dis Surveillane & Contr (Summer Term 2014)
  • PUH332 - Communicable Disease (Spring Term 2016)
  • PUH332 - Communicable Disease (Spring Term 2017)
  • PUH434 - Global Communicable Disease (Spring Term 2018)
  • Education And Training

  • Harvard University, Cambridge School of Public Health: Tropical Medicine, Postdoctoral Research
  • Doctor of Medicine, University of Wisconsin System : Madison 1982
  • Bachelor of Science or Mathematics in Biochemistry, University of Wisconsin System : Madison 1974
  • Full Name

  • Craig Wilson